A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia



Status:Completed
Conditions:Schizophrenia
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 40
Updated:2/1/2019
Start Date:March 26, 2014
End Date:June 20, 2017

Use our guide to learn which trials are right for you!

The primary aim of the study is to determine the efficacy of adjunctive valacyclovir, in
comparison to placebo, to improve visual (Brief Visuospatial Memory Test) and working
(composite score of the Spatial Span and Letter Number Span tests) memory in individuals who
are HSV-1 positive and early in the course of schizophrenia.

We hypothesize that individuals who are HSV-1 positive, but not those who are HSV-1 negative,
will demonstrate significant valacyclovir efficacy for visual and working memory.

One hundred and seventy-five participants (N=70 HSV-1 seropositive and N=105 HSV-1
seronegative) will be randomized 1:1 to receive adjunctive valacyclovir or adjunctive placebo
for a 16 week period. The primary outcome that will be assessed is improvement in changes in
visual and working memory scores in HSV-1 positive and negative participants over the course
of the study. We will also measure the overall cognitive functioning and the severity of
psychiatric symptoms over the course of the study and will evaluate the tolerability and
safety of valacyclovir treatment in this population. In addition, we will explore the
relationship between changes in the levels of inflammatory markers (HSV2, CMV, EBV, CRP, and
Toxoplasmosis) and treatment response over the course of the study.

Inclusion Criteria:

- 18 to 40 years of age at study entry.

- Able to give written informed consent.

- DSM IV-TR Diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder as
confirmed by Structured Clinical Interview for DSM-IV-TR (SCID)

- Onset of schizophreniform disorder, schizophrenia, or schizoaffective disorder within
the past eight years as defined by first medical records documentation of these
conditions

- Outpatient or inpatient.

- Clinical stability as defined by:

1. CGI-S score of less than or equal to 4 (moderately ill) at randomization AND

2. Participants must not have experienced an exacerbation of their illness within 4
weeks prior to randomization leading to an intensification of psychiatric care in
the opinion of the investigator. Examples of intensification of care include, but
are not limited to: inpatient hospitalization, day/partial hospitalization,
outpatient crisis management, or psychiatric treatment in an emergency room AND

3. Antipsychotic treatment stability for at least 4 weeks prior to randomization (no
change in antipsychotic dosing, addition of any new antipsychotic medication, or
discontinuing an antipsychotic medication)

- Fluent in English.

- Female participants of childbearing potential must test negative for pregnancy at
screening visit and agree to use a single, effective, medically acceptable method of
birth control for the duration of the study.

Exclusion Criteria:

- Known IQ less than 70 as determined by medical history.

- IV drug use within previous three month prior to study entry.

- Any serious active medical condition that affects brain or cognitive functioning
(e.g., epilepsy, serious head injury, brain tumor or other neurological disorder) in
the investigator's opinion.

- Known medical history of Human Immunodeficiency Virus (HIV)

- Receipt of valacyclovir or chemically-related medication within 2 weeks prior to
randomization.

- History of hypersensitivity to valacyclovir or acyclovir as determined by self-report
and medical history.

- DSM-IV diagnosis of substance dependence within 3 months of study entry (with the
exception of nicotine or caffeine dependence).

- Participants who have participated in a clinical trial with any pharmacological
treatment intervention for which they received study-related medication in the 4 weeks
prior to screening AND participants currently receiving treatment (within 1 dosing
interval plus 4 weeks) with an investigational depot formulation of an antipsychotic
medication.

- Females who are pregnant or planning to become pregnant or breastfeeding or planning
to do so during the study period.

- Participants with current acute, serious, or unstable medical conditions, including,
but not limited to: inadequately controlled diabetes, asthma, COPD, recent
cerebrovascular accidents, acute systemic infection or immunologic disease, unstable
cardiovascular disorders, malnutrition, or hepatic or renal disease, renal including
renal failure, gastroenterologic, respiratory, endocrinologic, neurologic, hematologic
including thrombotic thrombocytopenia purpura/hemolytic uremic syndrome, or infectious
diseases

- Participants who require concomitant treatment with any other medication other than
those allowed as specified in Attachment 2, or with any other medication specifically
excluded in Attachment 2.

- Clinically significant electrocardiogram (ECG) abnormality prior to randomization as
defined by: participants with a corrected QT interval (Bazett's; QTcB) >450 msec
(male) or >470 msec (female) prior to randomization. Repeat ECGs will be conducted at
the discretion of the principal investigator or medical designee.

- Test positive for (1) Hepatitis C virus antibody, (2) Hepatitis B surface antigen
(HBsAg) with or without positive Hepatitis B core total antibody.

- Participants with moderate to severe renal impairment as defined by creatinine
clearance (CrCl) < 60 ml/min (measured by the Cockcroft-Gault equation) at screening.

- Participants with hepatic impairment as defined by liver transaminases or total
bilirubin > 3 × upper limit of normal (ULN).

- Participants considered a high risk for suicidal acts - active suicidal ideation as
determined by clinical interview OR any suicide attempt in 90 days prior to screening.

- Participants who demonstrate overtly aggressive behavior or who are deemed to pose a
homicidal risk in the investigator's opinion.

- Participants currently receiving cognitive remediation therapy at time of study entry

- Participants who have had electroconvulsive therapy (ECT) within 12 months of study
entry or who will have ECT at any time during the study.
We found this trial at
13
sites
Indianapolis, Indiana 46222
Principal Investigator: Alan Breier, MD
Phone: 317-941-4287
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
Principal Investigator: Stephen Marder, MD
Phone: 310-206-8980
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Baltimore, Maryland 21228
Principal Investigator: Robert Buchanan, MD
Phone: 410-402-6060
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Elizabeth Zarate-Rowell, MD
Phone: 562-748-4999
?
mi
from
Bellflower, CA
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Alan Breier, MD
Phone: 317-880-8494
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Lauderhill, Florida 33319
Principal Investigator: Rishi Kakar, MD
Phone: 954-769-1477
?
mi
from
Lauderhill, FL
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Deepak C D'Souza, MD
Phone: 203-974-7775
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
Riverside, California 92506
Principal Investigator: Gerald Maguire, MD
Phone: 951-300-4924
?
mi
from
Riverside, CA
Click here to add this to my saved trials
Rockville, Maryland 20850
Principal Investigator: Robert Litman, MD
Phone: 301-251-4702
?
mi
from
Rockville, MD
Click here to add this to my saved trials
Santa Ana, California 92705
Principal Investigator: Evagelos Coskinas, MD, PhD
Phone: 714-979-4101
?
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Towson, Maryland 21204
Principal Investigator: Faith Dickerson, PhD
Phone: 410-938-4356
?
mi
from
Towson, MD
Click here to add this to my saved trials
Tulsa, Oklahoma 74136
Phone: 918-502-5179
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
1001 North Minneapolis Street
Wichita, Kansas 67214
?
mi
from
Wichita, KS
Click here to add this to my saved trials